var data={"title":"Alitretinoin (Systemic) (United States: Not available) (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alitretinoin (Systemic) (United States: Not available) (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/577210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alitretinoin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alitretinoin (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504540\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Toctino</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504542\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-inflammatory Agent;</li>\n      <li>\n        Immunomodulator, Systemic;</li>\n      <li>\n        Retinoic Acid Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504602\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Eczema of the hand (severe, chronic):</b> Oral: Initial: 30 mg once daily; may consider dose reduction to 10 mg once daily for intolerable side effects; usual range: 10 to 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Therapy duration:</i> 12 to 24 weeks; consider discontinuation of therapy if severe disease is still present after initial 12 weeks of therapy or if clear or almost clear hands occur prior to 24 weeks. Patients who relapse may benefit from additional treatment; females who relapse must follow the same contraceptive protocol as when initiating therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504596\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504597\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504598\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504599\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Consider dose reduction to 10 mg once daily for intolerable side effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504614\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toctino: 10 mg, 30 mg [contains soybean oil]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504609\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45749215\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Prescriptions must be limited to a 30-day supply for women of childbearing potential; further treatment requires a new prescription. The evaluation of pregnancy test results and the issuance and dispensing of a prescription should preferably occur on the same day. Alitretinoin should be dispensed within 7 days of a medically supervised pregnancy test.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504603\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer once daily with a main meal, preferably at the same time each day. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104425\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504544\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Eczema of the hand:</b> Treatment of severe chronic hand eczema refractory to high-potency topical corticosteroids</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504539\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alitretinoin may be confused with altretamine, isotretinoin, tretinoin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Panretin is a topical preparation of alitretinoin available in the US.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20788365\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (11% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides (30 mg: 35%; 10 mg: 17%), increased LDL cholesterol (&gt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (2% to 6%), hypertension (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (3%), dizziness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (2% to 7%), cheilosis (4% to 6%), xeroderma (3%), cheilitis (2%), alopecia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol (5% to 10%), decreased thyroid hormones (TSH and T4, reversible: 3% to 10%), hypercholesterolemia (1% to 10%), decreased serum iron (1% to 5%), high total iron binding capacity (1% to 5%), weight gain (1%), hot flash (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), xerostomia (3%), dyspepsia (1%), upper abdominal pain (1%), vomiting (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Reticulocytopenia (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (2% to 3%), arthralgia (2%), back pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Dry eye syndrome (2% to 3%), conjunctivitis (2%), abnormal sensation in eyes (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (6%), pharyngitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute pancreatitis, aggressive behavior, anaphylaxis, ankylosing spondylitis, anxiety, blurred vision, cataract, decreased hematocrit, decreased hemoglobin, decreased red blood cells, epistaxis, exfoliation of skin, exostosis, eye irritation, hypersensitivity reaction, increased serum transaminases, inflammatory bowel disease, mood changes, nail disease, nocturnal amblyopia, peripheral edema, pruritus, psychotic symptoms, skin photosensitivity, skin rash, suicidal ideation, suicidal tendencies, thrombocythemia, tinnitus, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504553\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to alitretinoin, other retinoids, or any component of the formulation (including allergy to peanut or soya); pregnancy; women of childbearing potential unless all of the conditions of the Pregnancy Prevention Program are met; breast-feeding; hepatic impairment; severe renal impairment; uncontrolled hypercholesterolemia; uncontrolled hypertriglyceridemia; uncontrolled hypothyroidism; hypervitaminosis A; fructose intolerance; concurrent use of tetracyclines</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504545\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Retinoids enhance the effects of ultraviolet (UV) light; avoid excessive exposure to sunlight or sun lamp. Instruct patients to apply sun protectant (&ge;15 SPF), skin moisturizers, and lip balm when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transient and reversible transaminase elevations have been observed with systemic retinoids; consider dose reduction or discontinuation of therapy for persistent clinically relevant effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercholesterolemia/hypertriglyceridemia: Associated with hypercholesterolemia and hypertriglyceridemia; discontinue use for uncontrollable hypertriglyceridemia. Obese patients or patients with increased alcohol use, diabetes mellitus, or a family history of hypertriglyceridemia may be at an increased risk of developing hypertriglyceridemia. Patients at high risk for cardiac events should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (eg, anaphylaxis, allergic cutaneous reactions, allergic vasculitis) have been reported rarely. Interrupt therapy for severe allergic reactions and treat as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory bowel disease: Onset of inflammatory bowel disease (IBD) in patients with no history of gastrointestinal disorders has been observed with systemic retinoids; discontinue use immediately for abdominal pain, rectal bleeding, or severe diarrhea. Rule out IBD in patients with severe diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: <b>[Canadian Boxed Warning]: Retinoids (including alitretinoin) have been associated with the development of benign intracranial hypertension, and in some cases involving concomitant tetracycline use. Discontinue use immediately for signs/symptoms of benign intracranial hypertension (eg, headache, abnormal vision, papilledema, nausea, vomiting).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal effects: Use of alitretinoin has been associated with myalgia and arthralgia. Bone changes (eg, premature epiphyseal closure, hyperostosis, calcification of tendons/ligaments) have been observed with other systemic retinoids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Corneal opacities, keratitis, and conjunctivitis have occurred with systemic retinoids. Dry eyes and/or impaired night vision have also been reported with use; may be reversible upon discontinuation of therapy. Patients with dry eyes should be monitored for keratitis. Caution patients with regard to driving or operating machinery. Intolerance to contact lens (due to dry eyes) may be observed. Ophthalmologic exam may be warranted for ongoing visual disturbances and, if necessary, discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Acute pancreatitis has been reported, usually associated with elevated serum triglycerides. Discontinue if symptoms of pancreatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric effects: Systemic retinoid use may cause or aggravate depression, anxiety, psychosis, aggressive or violent behavior, and changes in mood; suicidal thoughts and actions have also been reported (rare). Prior to initiation of therapy and routinely during therapy, all patients should be evaluated for symptoms of depression or suicidal thoughts. Caregivers should be informed of the potential for psychiatric effects. Therapy should be discontinued if patients develop depression, aggression, mood disturbance, or psychosis, although discontinuation of treatment alone may not be sufficient to relieve symptoms; further evaluation may be necessary. Use with extreme caution in patients with a history of psychiatric disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid effects: Associated with reversible reductions in thyroid-stimulating hormone (TSH) and T<sub>4</sub> (free thyroxine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Use with caution in patients with diabetes mellitus; impaired glucose control has been reported with other retinoids. Monitor blood glucose periodically in patients with known or suspected diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use should be reserved for patients nonresponsive to potent topical corticosteroids and/or other measures (eg, avoidance of irritants/allergens, skin protection).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood donation: Patients should not donate blood during therapy and for 1 month after discontinuing therapy due to the potential risk to the fetus of a pregnant transfusion recipient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[Canadian Boxed Warning]: Alitretinoin is a known teratogen and is contraindicated in pregnancy. Females must avoid becoming pregnant while receiving alitretinoin and for at least 1 month after discontinuation of therapy. Discontinue immediately if pregnancy is discovered during treatment or within 1 month after discontinuation.</b> Fetal abnormalities and spontaneous abortion may occur. The risk for severe birth defects is high, with any dose or even with short treatment duration. <b>Only physicians familiar with systemic retinoid therapy should prescribe alitretinoin. Females of childbearing potential must be able to fulfill all conditions for use prior to initiating therapy (consult manufacturer labeling for further detail). Physicians are required to use the Toctino Pregnancy Prevention Program, which includes comprehensive information regarding conditions that must be met prior to initiating therapy, birth control options, potential risks of therapy, informed consent, and monthly pregnancy reminders.</b> Two effective and reliable means of birth control should be used simultaneously for at least 1 month prior to starting therapy during therapy, and for at least 1 month after treatment. Two negative pregnancy tests (sensitivity at least 25 milliunits/mL) and the onset of next menses for 2 or 3 days are required prior to initiating therapy. Refer to Pregnancy considerations for more detailed discussion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20797112\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20797110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89683&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Alitretinoin (Systemic). Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C8 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C8 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Alitretinoin (Systemic). Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Alitretinoin (Systemic). Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Alitretinoin (Systemic) may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504564\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food significantly enhances systemic exposure and decreases variability in exposure. Management: Administer with a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504548\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[Canadian Boxed Warning]: Alitretinoin is a known teratogen and is contraindicated in pregnancy. Females must avoid becoming pregnant while receiving alitretinoin and for at least 1 month after discontinuation of therapy. Discontinue immediately if pregnancy is discovered during treatment or within 1 month after discontinuation.</b> Fetal abnormalities and spontaneous abortion may occur. The risk for severe birth defects is high, with any dose or even with short treatment duration. If treatment with alitretinoin is required in women of childbearing potential, two effective and reliable forms of birth control should be used simultaneously for at least 1 month prior to starting therapy, during therapy, and for at least 1 month after treatment. Two negative pregnancy tests (sensitivity at least 25 milliunits/mL) and onset of next menses for 2 or 3 days are required prior to initiating therapy. Patients should be advised of the potential harm to the fetus and the physician and patient should discuss the desire to maintain the pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Only physicians familiar with systemic retinoid therapy should prescribe alitretinoin. Females of childbearing potential must be able to fulfill all conditions for use prior to initiating therapy (consult manufacturer labeling for further detail). Physicians are required to use the Toctino Pregnancy Prevention Program, which includes comprehensive information regarding conditions that must be met prior to initiating therapy, birth control options, potential risks of therapy, informed consent, and monthly pregnancy reminders.</b> Even women with amenorrhea, a history of infertility, or those who claim an absence of sexual activity must comply with these conditions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Small amounts of alitretinoin have been detected in the semen of some healthy male volunteers, although accumulation in the semen is not anticipated. Systemic exposure of female partners or fetus is expected to be negligible. The manufacturer labeling suggests that there is no apparent fetal risk in pregnant females whose male partners are receiving alitretinoin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504547\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if alitretinoin is excreted in breast milk; however, it is highly lipophilic and is likely excreted in human breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is contraindicated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504607\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to initiating therapy in female patients, perform two pregnancy tests (sensitivity at least 25 milliunits/mL); second test must be performed &le;11 days prior to initiation. Thereafter, perform monthly pregnancy tests during therapy and at 1 month following discontinuation. Serum lipids (particularly if at high risk for cardiac events, obese patients and patients with diabetes) at baseline and then monthly until lipid response is established and again at discontinuation; hepatic function; serum glucose (periodically in patients with known or suspected diabetes mellitus, obese patients, and patients with cardiovascular risk factors); thyroid function. Signs/symptoms of depression, mood alteration, psychosis, aggression, hypersensitivity, and pancreatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504567\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to both retinoid acid receptor (RAR) and retinoid X receptor (RXR); anti-inflammatory and immunomodulating effects occur through down-regulation of CXCR3 ligands and CCL20 chemokine expression in cytokine-induced dermal cells and suppressed expansion of cytokine-induced leukocytes and antigen presenting cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504570\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Serum concentrations of endogenous alitretinoin return to normal range within 48 to 72 hours after discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Variable and dose-proportional (not consistently absorbed in fasted state)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: &gt;14 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2C9, 2C8, and 3A4 to metabolites; Major metabolite: 4-oxo-alitretinoin (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Systemic exposure is enhanced by food (Schmitt-Hoffman 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Alitretinoin: 9 hours; 4-oxo-alitretinoin: 10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 3 to 4 hours (Weber 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (63% as metabolites); feces (~30% as metabolites) (Schmitt-Hoffman 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26531097\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alitoc (KR);</li>\n      <li>Toctino (AT, BG, CH, DE, DK, EE, ES, FI, FR, GB, IS, LT, LV, MT, NO, PL, RO, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruzicka T, Lynde CW, Jemec GB, et al, &ldquo;Efficacy and Safety of Oral Alitretinoin (9-Cis Retinoic Acid) in Patients With Severe Chronic Hand Eczema Refractory to Topical Corticosteroids: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial,&rdquo; <i>Br J Dermatol</i>, 2008, 158(4):808-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alitretinoin-systemic-united-states-not-available-systemic-drug-information/abstract-text/18294310/pubmed\" target=\"_blank\" id=\"18294310\">18294310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmitt-Hoffmann AH, Roos B, Sauer J, et al, &ldquo;Influence of Food on the Pharmacokinetics of Oral Alitretinoin (9-cis Retinoic Acid),&rdquo; <i>Clin Exp Dermatol</i>, 2011, 36(Suppl 2):18-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alitretinoin-systemic-united-states-not-available-systemic-drug-information/abstract-text/21443600/pubmed\" target=\"_blank\" id=\"21443600\">21443600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmitt-Hoffmann AH, Roos B, Schoetzau A, et al, &ldquo;Oral Alitretinoin: A Review of the Clinical Pharmacokinetics and Pharmacodynamics,&rdquo; <i>Expert Rev Clin Pharmacol</i>, 2012, 5(4):373-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alitretinoin-systemic-united-states-not-available-systemic-drug-information/abstract-text/22943117/pubmed\" target=\"_blank\" id=\"22943117\">22943117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toctino (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber C and Dumont E, &ldquo;Pharmacokinetics and Pharmacodynamics of 9-cis-Retinoic Acid in Healthy Men,&rdquo; <i>J Clin Pharmacol</i>, 1997, 37(7):566-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alitretinoin-systemic-united-states-not-available-systemic-drug-information/abstract-text/9243349/pubmed\" target=\"_blank\" id=\"9243349\">9243349</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89683 Version 74.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20504540\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20504542\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20504602\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20504596\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20504597\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20504598\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20504599\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F20504614\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F20504609\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F45749215\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20504603\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104425\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20504544\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20504539\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20788365\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20504553\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20504545\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20797112\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20797110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F20504564\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20504548\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20504547\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20504607\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20504567\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20504570\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26531097\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89683|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alitretinoin-systemic-patient-drug-information\" class=\"drug drug_patient\">Alitretinoin (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}